

SUPPLEMENTARY DATA

Supplementary Table 1. Medline Search Strategy

1.	Diabetes Mellitus, Type 1
2.	("insulin* depend*" or "insulin?depend*").mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
3.	("typ? 1 diabet*" or "typ? I diabet*" or "typ?1 diabet*" or "typ?I diabet*").mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
4.	((auto-immun* or autoimmun* or sudden onset) adj2 diabet*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
5.	(insulin* defic* adj2 absolut*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
6.	(IDDM or T1DM or T1D).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
7.	Hypoglycemia
8.	hypoglyc?emi*.mp.
9.	(low adj3 glucose).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
10.	7 or 8 or 9
11.	1 or 2 or 3 or 4 or 5 or 6
12.	((impair* or reduc* or declin* or defect* or inadequate or fault* or insufficient or fail* or low* or los* or blunt* or flat* or abnormal* or deteriorat* or dysfunction*) adj10 (aware* or perce* or recogni* or threshold or sens* or level or response or symptom* or arous* or counter?regulat* or hormon* or neuroendocrine or function* or activat* or catecholamine* or noradrenaline or adrenaline or norepinephrine or epinephrine or cortiso* or "growth hormone" or GH or glucagon) adj10 (hypoglyc?emi* or glyc?emi*)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
13.	((hypoglyc?emi* or hypo) adj3 (stop* or avoid* or cessation or cease* or arrest* or prevent* or halt* or limit* or preclud* or restrict* or obviate* or eliminat* or remov*)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
14.	Awareness
15.	((unawareness adj10 (hypoglyc?emi* or "hypo"))).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
16.	12 or 13 or 14 or 15
17.	10 and 11 and 16

SUPPLEMENTARY DATA

Supplementary Table 2a. Individual effect sizes of included studies for educational intervention in meta-analysis.

Study	N	SMD	SE	95% CI	t	P
Hermanns 2013 DTTP	79	0.321	0.159	0.00607 to 0.636		
Hermanns 2013 PRIMAS	81	0.351	0.158	0.0399 to 0.662		
Hermanns 2010 DTTP	70	0.651	0.173	0.309 to 0.992		
Hermanns 2010 HyPOS	70	0.653	0.173	0.312 to 0.994		
Schachinger 2005 BGAT-3	56	0.593	0.192	0.213 to 0.973		
DeZoysa 2014 DAFNE-HART	23	0.94	0.306	0.324 to 1.557		
Hopkins 2012 DAFNE	539	0.137	0.0609	0.0176 to 0.257		
Kubiak 2006 Hypoglycemia-specific program	92	0.311	0.148	0.0196 to 0.603		
Total (fixed effects)	1010	0.296	0.0447	0.208 to 0.384	6.616	<0.001
Total (random effects)	1010	0.44	0.0954	0.253 to 0.628	4.616	<0.001

Supplementary Table 2b. Test for heterogeneity of included studies in meta-analysis

Q	22.2802
DF	7
Significance level	P=0.0023
I ² (Inconsistency)	68.58%
95% CI for I ²	34.20 to 85.00